TD Cowen's investment themes for 2025: Spotting opportunities and risks
Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD Cowen report on the big investment themes of 2025, including shifting ...
Thomas: The word of the day is choppy.
Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, describes the current market as "choppy," indicating the need for careful navigation. She emphasizes the importance of ...
Arthur J. Gallagher upgraded to Buy from Hold at TD Cowen
TD Cowen analyst Andrew Kligerman upgraded Arthur J. Gallagher (AJG) to Buy from Hold with a price target of $377, up from $295, following the ...
Trump's Ozempic tariffs, Zepbound on Medicare, and rising drug prices: Pharma news roundup
El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...
TD Cowen Sticks to Their Buy Rating for Alphatec Holdings (ATEC)
TD Cowen analyst Josh Jennings maintained a Buy rating on Alphatec Holdings (ATEC – Research Report) yesterday. The company’s shares closed ...